| Hypertension potential efficacy biomarker for metastatic renal cell carcinoma - HemOncToday |
|
|
HemOncToday Patients who developed sunitinib-associated hypertension while being treated for metastatic renal cell carcinoma lived more than 30 months longer than patients with normal blood pressure, according to the results of a recently published study. |